

22 May 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo's GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 20 May 2022, including: a US setback for [UCB S.A.](#); [Eli Lilly and Company](#) challenges [Novo Nordisk A/S's](#) GLP franchise; [Seagen Inc.](#) searches for CEO after scandal; [Jiangsu Hengrui Medicine Co., Ltd.](#) hopes for US PD-1 success; and a look ahead at ASCO.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx](#)" - Scrip, 13 May, 2022.)

(Also see "[Lilly's Mounjaro Diabetes Approval Is First Challenge To Novo's GLP-1 Franchise](#)" - Scrip, 13 May, 2022.)

(Also see "[Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal](#)" - Scrip, 16 May, 2022.)

(Also see "[Hengrui's PD-1 Camrelizumab Moves Step Closer To US Filing](#)" - Scrip, 16 May, 2022.)

(Also see "[*Five Late-Breaking Studies To Look Out For At ASCO*](#)" - Scrip, 18 May, 2022.)

[Click here to explore this interactive content online](#) ✎